Under this multi-year agreement, Burnham will provide J&JPRD with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.
"This collaboration offers great synergies," said Dr. John Reed, Burnham President and CEO, Professor and Donald Bren Presidential Chair. "Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential."
About Burnham Institute for Medical Research
Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest growing research institutes in the country. The Institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies.
In September 2008, Burnham was awarded a prestigious six-year, $98 million Molecular Libraries Probe Production Centers Network (MLPCN) grant from the National Institutes of Health, and is one of four comprehensive small-molecule screening and discovery centers in the nation.
Burnham is a nonprofit, public benefit corporation. For more information, please visit www.burnham.org.
Media Contacts: Josh Baxt Burnham Institute for Medical Research jbaxt@burnham.org 858-795-5236
Martina Schwarzkopf, Ph.D. Russo Partners, LLC martina.schwarzkopf@russopartnersllc.com 212-845-4292
Source: Burnham Institute for Medical Research
